356535-20-1

Basic information

• Product Name: 4-[(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)methyl]benzoic acid
• Synonyms: 4-[(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)methyl]benzoic acid
• CAS NO: 356535-20-1
• Molecular Weight: 220.185
• Mol File: 356535-20-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-[(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)methyl]benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)methyl]benzoic acid(356535-20-1)
• EPA Substance Registry System: 4-[(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)methyl]benzoic acid(356535-20-1)

Safety Data

• Hazardous Substances Data: 356535-20-1(Hazardous Substances Data)

Upstream product

• 356535-26-7 methyl (Z)-4-(2-amino-2-(hydroxyimino)ethyl)benzoate 
• 76469-88-0 methyl 4-(cyanomethyl)benzoate 
• 34040-64-7 p-methyloxycarbonylbenzyl chloride 

Downstream Products

• 1026575-13-2 ((S)-4-(2-Benzyloxycarbonylamino-acetyl)-2-oxo-3-{[4-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-ylmethyl)-benzoylamino]-methyl}-piperazin-1-yl)-acetic acid 

Relevant articles and documents

Potent dibasic GPIIb/IIIa antagonists with reduced prolongation of bleeding time: Synthesis and pharmacological evaluation of 2-oxopiperazine derivatives

A series of 2-oxopiperazine derivatives, possessing basic moieties at the 3- and the 4-positions, were synthesized and evaluated for their abilities to inhibit platelet aggregation and for their effects on bleeding time. Among the compounds, 2-[(3S)-4-[2-[(4-guanidinobenzoyl)amino] acetyl]3-[3-[(4-guanidinobenzoyl)amino]propyl]-2-oxopiperazinyl]acetic acid (12c) showed a potent inhibitory effect on platelet aggregation and good dissociation between the efficacy and the bleeding side effect. Intravenous infusion of compound 12c at 1.6 μg/mL/min. completely prevented arterial thrombus formation induced by endothelial injury in guinea pigs. The dose of 12c that prolonged the bleeding time to three times the control value was 5.8/μg/mL/min. These results suggest that compound 12c might be useful in the clinical treatment of thrombotic diseases, and we selected 12c (TAK-024) as a candidate for the clinical trials.